发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Lipid-lowering therapy in patients with a 'normal' LDL-C. 低密度脂蛋白胆固醇 "正常 "患者的降脂治疗。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.019
{"title":"Lipid-lowering therapy in patients with a 'normal' LDL-C.","authors":"","doi":"10.18773/austprescr.2024.019","DOIUrl":"10.18773/austprescr.2024.019","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"94"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216912/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499735","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nirsevimab for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. 用于预防新生儿和婴儿呼吸道合胞病毒（RSV）下呼吸道疾病的 Nirsevimab。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.027
{"title":"Nirsevimab for prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants.","authors":"","doi":"10.18773/austprescr.2024.027","DOIUrl":"10.18773/austprescr.2024.027","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"102-103"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216910/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Deprescribing antihypertensive drugs in frail older adults. 对年老体弱者停用降压药。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.023
Emily Reeve, Danijela Gnjidic, Aili V Langford, Sarah N Hilmer
{"title":"Deprescribing antihypertensive drugs in frail older adults.","authors":"Emily Reeve, Danijela Gnjidic, Aili V Langford, Sarah N Hilmer","doi":"10.18773/austprescr.2024.023","DOIUrl":"10.18773/austprescr.2024.023","url":null,"abstract":"<p><p>Antihypertensive drugs are commonly used by older adults because of the high prevalence of cardiovascular disease and its risk factors, and the increased absolute benefit of blood pressure reduction with increasing age. Clinical trials of blood pressure reduction in older adults have generally excluded older adults with multimorbidity, frailty and limited life expectancy. In this population, the benefit-harm ratio of aggressive blood pressure lowering may become unfavourable; a more relaxed blood pressure target may be appropriate; and deprescribing (cessation or dose reduction) of one or more antihypertensive drugs can be considered. Before deprescribing an antihypertensive drug, it is important to consider other indications for which it may have been prescribed (e.g. heart failure with reduced ejection fraction, diabetic nephropathy, atrial fibrillation). Evidence from randomised controlled deprescribing trials indicates that it is possible to deprescribe antihypertensives in frail older people. However, some patients may experience an increase in blood pressure that warrants restarting the drug. There are limited data on long-term outcomes (follow-up in deprescribing trials ranged from 4 to 56 weeks). The risk of adverse outcomes associated with deprescribing, such as withdrawal effects, can be minimised through appropriate planning, patient engagement, dose tapering and monitoring.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"85-90"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216913/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recombinant respiratory syncytial virus (RSV) vaccines for older adults, and pregnant women to prevent disease in their infant. 为老年人和孕妇提供重组呼吸道合胞病毒 (RSV) 疫苗，以预防婴儿患病。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.028
{"title":"Recombinant respiratory syncytial virus (RSV) vaccines for older adults, and pregnant women to prevent disease in their infant.","authors":"","doi":"10.18773/austprescr.2024.028","DOIUrl":"10.18773/austprescr.2024.028","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"100-101"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141500166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inclisiran for hypercholesterolaemia. 治疗高胆固醇血症的 Inclisiran。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.026
{"title":"Inclisiran for hypercholesterolaemia.","authors":"","doi":"10.18773/austprescr.2024.026","DOIUrl":"10.18773/austprescr.2024.026","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"98-99"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thiopurines and risk of lymphoproliferative disorders. 硫嘌呤与淋巴组织增生性疾病的风险
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.020
Varan Perananthan, Miles P Sparrow, Anna Foley
{"title":"Thiopurines and risk of lymphoproliferative disorders.","authors":"Varan Perananthan, Miles P Sparrow, Anna Foley","doi":"10.18773/austprescr.2024.020","DOIUrl":"10.18773/austprescr.2024.020","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"91-93"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216916/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Digital health: dashboards, dashboards, everywhere. 数字健康：仪表盘、仪表盘，无处不在。
IF 2.7
Australian Prescriber Pub Date : 2024-04-01 DOI: 10.18773/austprescr.2024.009
{"title":"Digital health: dashboards, dashboards, everywhere.","authors":"","doi":"10.18773/austprescr.2024.009","DOIUrl":"10.18773/austprescr.2024.009","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 2","pages":"46-47"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11081738/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Faricimab for neovascular age-related macular degeneration and diabetic macular oedema. 治疗新生血管性老年黄斑变性和糖尿病性黄斑水肿的 Faricimab。
IF 2.7
Australian Prescriber Pub Date : 2024-04-01 DOI: 10.18773/austprescr.2024.013
{"title":"Faricimab for neovascular age-related macular degeneration and diabetic macular oedema.","authors":"","doi":"10.18773/austprescr.2024.013","DOIUrl":"10.18773/austprescr.2024.013","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 2","pages":"66-67"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11081741/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based management of menopause. 以证据为基础的更年期管理。
IF 2.7
Australian Prescriber Pub Date : 2024-04-01 DOI: 10.18773/austprescr.2024.017
{"title":"Evidence-based management of menopause.","authors":"","doi":"10.18773/austprescr.2024.017","DOIUrl":"10.18773/austprescr.2024.017","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 2","pages":"43-45"},"PeriodicalIF":2.7,"publicationDate":"2024-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11081740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140913058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
TGA Medicines Safety Update and Australian Prescriber-back to the future (take 2). 澳大利亚药品管理局《药品安全最新信息》和《澳大利亚开处方者--面向未来》（第二部分）。
IF 2.7
Australian Prescriber Pub Date : 2024-02-01 DOI: 10.18773/austprescr.2024.003
{"title":"TGA <i>Medicines Safety Update</i> and <i>Australian Prescriber</i>-back to the future (take 2).","authors":"","doi":"10.18773/austprescr.2024.003","DOIUrl":"10.18773/austprescr.2024.003","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 1","pages":"29"},"PeriodicalIF":2.7,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10911834/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140040931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信